FDA Inspection 1168775 — Jeremy Abramson MD
The FDA completed an inspection of Jeremy Abramson MD on April 25, 2022 in Boston, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 25, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Boston, MA (United States)
Additional Details
Clinical Investigator (CI)